Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET-MS: S103 Cells in Progressive or Refractory Multiple Sclerosis
NCT07587125Phase 1Recruiting
- Sponsor
- Xijing Hospital
- Start
- May 2026
- Primary completion
- Nov 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in multiple sclerosis (MS), sponsored by Xijing Hospital. Primary endpoints: Dose-Limiting Toxicities and Adverse Events. Started May 2026; status: recruiting.
02
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07587125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07587125.